Corrigendum Open Access | 10.1172/jci.insight.165688
Find articles by Sharma, G. in: JCI | PubMed | Google Scholar
Find articles by Ojha, R. in: JCI | PubMed | Google Scholar
Find articles by Noguera-Ortega, E. in: JCI | PubMed | Google Scholar
Find articles by Rebecca, V. in: JCI | PubMed | Google Scholar
Find articles by Attanasio, J. in: JCI | PubMed | Google Scholar
Find articles by Liu, S. in: JCI | PubMed | Google Scholar
Find articles by Piao, S. in: JCI | PubMed | Google Scholar
Find articles by Lee, J. in: JCI | PubMed | Google Scholar
Find articles by Nicastri, M. in: JCI | PubMed | Google Scholar
Find articles by Harper, S. in: JCI | PubMed | Google Scholar
Find articles by Ronghe, A. in: JCI | PubMed | Google Scholar
Find articles by Jain, V. in: JCI | PubMed | Google Scholar
Find articles by Winkler, J. in: JCI | PubMed | Google Scholar
Find articles by Speicher, D. in: JCI | PubMed | Google Scholar
Find articles by Mastio, J. in: JCI | PubMed | Google Scholar
Find articles by Gimotty, P. in: JCI | PubMed | Google Scholar
Find articles by Xu, X. in: JCI | PubMed | Google Scholar
Find articles by Wherry, E. in: JCI | PubMed | Google Scholar
Find articles by Gabrilovich, D. in: JCI | PubMed | Google Scholar
Find articles by Amaravadi, R. in: JCI | PubMed | Google Scholar
Published October 24, 2022 - More info
New strategies are needed to enhance the efficacy of anti–programmed cell death protein antibody (anti–PD-1 Ab) in cancer. Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of chloroquine derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti–PD-1 Ab in melanoma. The combination resulted in tumor growth impairment and improved survival in mouse models. Genetic suppression of core autophagy genes, but not Ppt1, in cancer cells reduced priming and cytotoxic capacity of primed T cells. Exposure of antigen-primed T cells to macrophage-conditioned medium derived from macrophages treated with PPT1 inhibitors enhanced melanoma-specific killing. Genetic or chemical Ppt1 inhibition resulted in M2 to M1 phenotype switching in macrophages. The combination was associated with a reduction in myeloid-derived suppressor cells in the tumor. Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase/stimulator of interferon genes/TANK binding kinase 1 pathway activation and the secretion of interferon-β in macrophages, the latter being a key component for augmented T cell–mediated cytotoxicity. Genetic Ppt1 inhibition produced similar findings. These data provide the rationale for this combination in melanoma clinical trials and further investigation in other cancers.
Gaurav Sharma, Rani Ojha, Estela Noguera-Ortega, Vito W. Rebecca, John Attanasio, Shujing Liu, Shengfu Piao, Jennifer J. Lee, Michael C. Nicastri, Sandra L. Harper, Amruta Ronghe, Vaibhav Jain, Jeffrey D. Winkler, David W. Speicher, Jerome Mastio, Phyllis A. Gimotty, Xiaowei Xu, E. John Wherry, Dmitry I. Gabrilovich, Ravi K. Amaravadi
Original citation: JCI Insight. 2020;5(17):e133225. https://doi.org/10.1172/jci.insight.133225
Citation for this corrigendum: JCI Insight. 2022;7(20):e165688. https://doi.org/10.1172/jci.insight.165688
The authors recently became aware that one of the p-TBK1 blot images presented in Figure 6C is the same as that presented in Figure 6D. The authors reviewed the original data and determined that the image in Figure 6C was incorrect. The correct version of Figure 6C is shown below, and the HTML and PDF versions have been updated.
The authors regret the error.
See the related article at PPT1 Inhibition enhances the anti-tumor activity of anti-PD-1 antibody in melanoma.